These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties. Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124 [TBL] [Abstract][Full Text] [Related]
4. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors. Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068 [TBL] [Abstract][Full Text] [Related]
5. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226 [TBL] [Abstract][Full Text] [Related]
6. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors. Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366 [TBL] [Abstract][Full Text] [Related]
8. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors. Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813 [TBL] [Abstract][Full Text] [Related]
9. Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors. Gopalsamy A; Ciszewski G; Shi M; Berger D; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R Bioorg Med Chem Lett; 2009 Dec; 19(24):6890-2. PubMed ID: 19884006 [TBL] [Abstract][Full Text] [Related]
10. Non-oxime pyrazole based inhibitors of B-Raf kinase. Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432 [TBL] [Abstract][Full Text] [Related]
12. 5-amino-pyrazoles as potent and selective p38α inhibitors. Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336 [TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent and selective type I B-Raf kinase inhibitors. Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors. Kim I; Song JH; Park CM; Jeong JW; Kim HR; Ha JR; No Z; Hyun YL; Cho YS; Sook Kang N; Jeon DJ Bioorg Med Chem Lett; 2010 Feb; 20(3):922-6. PubMed ID: 20053559 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). Moffett K; Konteatis Z; Nguyen D; Shetty R; Ludington J; Fujimoto T; Lee KJ; Chai X; Namboodiri H; Karpusas M; Dorsey B; Guarnieri F; Bukhtiyarova M; Springman E; Michelotti E Bioorg Med Chem Lett; 2011 Dec; 21(23):7155-65. PubMed ID: 22014550 [TBL] [Abstract][Full Text] [Related]
16. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors. Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists. Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703 [TBL] [Abstract][Full Text] [Related]
20. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase. Goldstein DM; Soth M; Gabriel T; Dewdney N; Kuglstatter A; Arzeno H; Chen J; Bingenheimer W; Dalrymple SA; Dunn J; Farrell R; Frauchiger S; La Fargue J; Ghate M; Graves B; Hill RJ; Li F; Litman R; Loe B; McIntosh J; McWeeney D; Papp E; Park J; Reese HF; Roberts RT; Rotstein D; San Pablo B; Sarma K; Stahl M; Sung ML; Suttman RT; Sjogren EB; Tan Y; Trejo A; Welch M; Weller P; Wong BR; Zecic H J Med Chem; 2011 Apr; 54(7):2255-65. PubMed ID: 21375264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]